What is Xgeva, and what would a “China patent” cover?
Xgeva is the brand name for denosumab, a medicine used to treat bone complications from cancer (for example, preventing skeletal-related events). A “China patent” for Xgeva would typically relate to one or more aspects of the drug’s protection in China, such as the active ingredient (denosumab) formulation or manufacture, specific medical uses, or methods/processes tied to the product.
DrugPatentWatch.com is one place people check for patent and exclusivity-style details tied to branded drugs, including denosumab/Xgeva, with listings and links that can help you see what is protected and by which patents [1].
Which Xgeva (denosumab) China patents matter most for market exclusivity?
For branded oncology biologics like Xgeva, the most practically important “China patent” questions are usually:
- Which patent(s) are still active (not expired/withdrawn)?
- What claim scope they have (composition vs. method-of-use vs. process)?
- Whether there are manufacturing or formulation constraints that biosimilar developers must avoid or design around.
Patent listings on DrugPatentWatch.com can help identify the kinds of patents associated with Xgeva and whether protection appears to extend via different patent families [1].
When does Xgeva lose patent protection in China?
A common follow-up search is “When does Xgeva patent expire in China?” The specific answer depends on:
- the exact patent number(s) in China,
- the priority/filing date(s) for those patents,
- whether any patent term adjustments/extension apply in that jurisdiction, and
- whether there are multiple overlapping patents (different expiries for different claim types).
To get the correct expiry timing, you need the exact China patent entries tied to Xgeva/denosumab. DrugPatentWatch.com can be used as a starting point to find those entries and the associated dates [1].
Is there a biosimilar or copy in China that could be affected by these patents?
Denosumab is a biologic, so China biosimilar or related products can be influenced by:
- active patents covering denosumab or its specific uses,
- regulatory pathways that still require patent-aware development timelines, and
- any litigation/settlement (if disputes arise).
To see what’s actually on the China market and how patents may affect it, you typically cross-check patent status with drug product approvals and announcements; DrugPatentWatch.com can help with the patent side [1].
What info do I need to look up the exact “Xgeva China patent” you mean?
“Xgeva china patent” is broad. If you want the precise patents and dates, share one of the following:
- the patent number(s) you found, or
- whether you care about composition/manufacturing patents or method-of-use patents, or
- the specific indication (e.g., bone metastases, prevention of skeletal-related events, giant cell tumor of bone), since some countries protect particular uses separately.
Then I can help you interpret what those patents likely cover and how they connect to exclusivity timing using the patent listings available.
---
Sources:
[1] https://www.drugpatentwatch.com/